Psoriatic lesions induced by antitumour necrosis factor-α treatment: Two cases [1]

British Journal of Dermatology

Volumn 151, Issue 2, 2004, Pages 506-507

  Dereure, O ^a   Guillot, B ^a   Jorgensen, C ^a   Cohen, J D ^a   Combes, B ^a   Guilhou, J J ^a  

^a HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ETANERCEPT; GOLD DERIVATIVE; INFLIXIMAB; METHOTREXATE; SALICYLIC ACID; STEROID; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; FEMALE; GOLD THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SKIN DEFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; LEG DERMATOSES; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4544372429     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06107.x     Document Type: Letter

References (6)

1. Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002; 61: 298-304.
2. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90.
3. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002; 46: 886-91.
4. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 1999; 131: 634.
5. Creaven PJ, Stoll HL Jr Response to tumor necrosis factor in two cases of psoriasis. J Am Acad Dermatol 1991; 24: 735-7.
6. Takematsu H, Ozawa H, Yoshimura T et al. Systemic TNF administration in psoriatic patients: a promising therapeutic modality in severe psoriasis. Br J Dermatol 1991; 124: 209-10.